



Patent on Provecs Medical's technology granted in Japan

Hamburg | 10 March 2011. Provecs Medical specialized in development of novel therapeutic vaccines for cancer and infectious diseases today announces the granting of a patent by the Japan Patent Office (JPO). The patent provides protection of Provecs Medical's product Immunalon®. In Japan, approximately 40 thousand novel cases of primary liver cancer, the first-in-man indication of Immunalon®, are being registered annually. This high incidence, at a tenfold higher level than in Germany, is considered to be associated with the high incidence of inflammatory liver conditions due to Hepatitis infections.

Patent protection in Japan assures a strong position in future partnering activities with Japanese pharma partners from the level of clinical development up to commercialization of Immunalon® in the important Japanese pharma market.

Provecs Medical is a privately owned biopharmaceutical company founded in 2007 as a spin-out of the University-Medical Center, Hamburg-Eppendorf in Hamburg, Germany. Provecs Medical specializes in the development of novel targeted immunotherapeutics for cancer and infectious diseases.

www.provecs.com

contact: schnieders@provecs.com